DK1674575T3 - Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse - Google Patents

Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse

Info

Publication number
DK1674575T3
DK1674575T3 DK05023967.2T DK05023967T DK1674575T3 DK 1674575 T3 DK1674575 T3 DK 1674575T3 DK 05023967 T DK05023967 T DK 05023967T DK 1674575 T3 DK1674575 T3 DK 1674575T3
Authority
DK
Denmark
Prior art keywords
methods
ligand
herpes virus
herpes simplex
hvem
Prior art date
Application number
DK05023967.2T
Other languages
English (en)
Inventor
Carl F Ware
Original Assignee
Jolla Inst Allergy Immunolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Inst Allergy Immunolog filed Critical Jolla Inst Allergy Immunolog
Application granted granted Critical
Publication of DK1674575T3 publication Critical patent/DK1674575T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
DK05023967.2T 2000-04-12 2001-04-11 Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse DK1674575T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54909600A 2000-04-12 2000-04-12
EP01926879A EP1274840B1 (en) 2000-04-12 2001-04-11 Ligand for herpes simplex virus entry mediator and methods of use

Publications (1)

Publication Number Publication Date
DK1674575T3 true DK1674575T3 (da) 2010-11-29

Family

ID=24191643

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05023967.2T DK1674575T3 (da) 2000-04-12 2001-04-11 Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse

Country Status (10)

Country Link
EP (2) EP1274840B1 (da)
JP (1) JP2003531152A (da)
AT (2) ATE483807T1 (da)
AU (1) AU5338701A (da)
CA (1) CA2406132C (da)
CY (1) CY1111293T1 (da)
DE (2) DE60129010T2 (da)
DK (1) DK1674575T3 (da)
ES (1) ES2352742T3 (da)
PT (1) PT1674575E (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010692A1 (ja) * 2005-07-19 2007-01-25 Japan Science And Technology Agency Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法
MX2011004467A (es) 2008-10-31 2011-07-28 Biogen Idec Inc Moleculas de objetivo light y usos de las mismas.
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
EP4126945A4 (en) 2020-04-01 2024-02-28 Avalo Therapeutics, Inc. METHODS AND TREATMENT INVOLVING EXCESS FREE LIGHT
CN111991551A (zh) * 2020-07-31 2020-11-27 中国人民解放军海军军医大学 Traf3半胱氨酸突变体在制备抗病毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
EP0904278A4 (en) * 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
CA2260767A1 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
EE05213B1 (et) * 1996-10-25 2009-10-15 Biogen, Incorporated Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon
WO1998018824A1 (en) * 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
EP0948543A1 (en) * 1996-12-12 1999-10-13 Genentech, Inc. Hvem polypeptides and uses thereof
JP2001524985A (ja) * 1997-05-12 2001-12-04 スミスクライン・ビーチャム・コーポレイション ヒト腫瘍壊死因子受容体様２（ｔｒ２）抗体
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6346388B1 (en) * 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
WO1999011662A1 (en) * 1997-09-05 1999-03-11 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
JP2002504333A (ja) * 1998-02-20 2002-02-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アポトーシス誘導分子ｉｉおよび使用方法
WO2000010591A1 (en) * 1998-08-18 2000-03-02 The Trustees Of The University Of Pennsylvania Peptides for inhibition of herpes simplex virus entry
CA2340686A1 (en) * 1998-09-03 2000-03-16 Samantha J. Busfield Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
PT1119370E (pt) * 1998-10-09 2006-09-29 Univ Emory Inversao do estado de choque sistemico e de dificuldade respiratoria originado por inducao viral por meio do bloqueio da via da linfotoxina beta
CA2367315A1 (en) * 1999-03-11 2000-09-14 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use

Also Published As

Publication number Publication date
DE60129010D1 (de) 2007-08-02
AU5338701A (en) 2001-10-30
CA2406132C (en) 2012-07-03
PT1674575E (pt) 2010-12-06
EP1674575A2 (en) 2006-06-28
ES2352742T3 (es) 2011-02-22
ATE483807T1 (de) 2010-10-15
EP1674575A3 (en) 2007-08-08
DE60129010T2 (de) 2008-02-28
EP1674575B1 (en) 2010-10-06
CA2406132A1 (en) 2001-10-25
EP1274840B1 (en) 2007-06-20
ATE365214T1 (de) 2007-07-15
JP2003531152A (ja) 2003-10-21
DE60143231D1 (de) 2010-11-18
EP1274840A2 (en) 2003-01-15
CY1111293T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
DE69842096D1 (de) Ligand des zelleintritt-vermittelnden proteins von herpes simplex virus und methoden zu dessen verwendung
ATE461938T1 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
CY1111293T1 (el) Συνδετης για μεσολαβητη εισοδου του ιου του απλου ερπητα και μεθοδοι χρησης
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DK0646595T3 (da) Nukleinsyrer-bindende oligomerer med N-forgrening til terapi og diagnostik
DE69731285D1 (de) Langwellig fluorezierende proteine
IS5217A (is) Bræðsluprótín á föstu svæði úr beta-breytivaxtarþætti (TGF-beta) af gerð II og ónæmisglóbúlíni
DE69321218T2 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
PT778891E (pt) Anticorpo monoclonal recombinante anti-rhesus d (d7c2)
DE69833283D1 (de) Tellurit-Glas, optischer Verstärker und Lichtquelle
IS6667A (is) Aðferðir til að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4 sameind
PT1157042E (pt) Produção de anticorpos tetravalentes
ATE315643T1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
WO2001079496A3 (en) Ligand for herpes simplex virus entry mediator and methods of use
DE59408308D1 (de) Nukleinsäure-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE69130845D1 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
FR2770516B1 (fr) COMPOSITION DE VERRE A BASE DE Ge-Ga-S PRESENTANT UNE CARACTERISTIQUE D'AMPLIFICATION DE LUMIERE ET APPAREIL DE COMMUNICATIONS OPTIQUES UTILISANT CETTE COMPOSITION
NO970130L (no) Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener